Table 2 KEGG enrichment analysis of identified DEG genes from control and citral treated samples in AGS.
Differential expressed genes | KEGG | Pathway | Genes involved | Log2(fold change) |
|---|---|---|---|---|
Up-regulated genes | hsa04101 | MAPK signaling pathway | HSPA1A, HSPA1B, GADDA45B | 8.09 |
hsa04064 | NF-kappa B signaling pathway | PLCG2 | 5.42 | |
hsa05200 | Pathways in cancer | PLCG2, HSP90AA1, CKS2 | 5.42 | |
hsa05215 | Prostate cancer | HSP90AA1 | 3.57 | |
hsa04151 | PI3K-Akt signaling pathway | HSP90AA1, ILR6 | 2.54 | |
hsa04115 | p53 signaling pathway | GADD45B | 2.54 | |
hsa04210 | Apoptosis | TNFRSF10D | 1.85 | |
hsa03040 | Spliceosome | SYF2 | 1.67 | |
Down-regulated genes | hsa05200 | Pathways in cancer | MSH6, MSH2, COL4A5, MMP1, CDK2, CCNE2, LAMB1, RAD51, PDGFRA | −1.17 |
hsa04110 | Cell cycle | CCNE1, CCNB3, CHEK1, CCNB1, CDK2, CDC7, E2F1, WEE1, CCNA2, MCM3, TTK, MCM6, CDC6, PKMYT1, BUB1B, PLK1, ESPL1 | −1.25 | |
hsa05222 | Small cell lung cancer | CCNE1, LAMB1, E2F1 | −1.25 | |
hsa04151 | PI3K-Akt signaling pathway | CCNE1, COL4A5, COL27A1, LAMB1, PDGFRA, PCK2 | −1.25 | |
hsa04115 | p53 signaling pathway | CCNB3, CCNB1, CDK2, CCNE2, RRM2, SERPINE1 | −1.27 | |
hsa05210 | Colorectal cancer | MSH2 | −1.65 | |
hsa05202 | Transcriptional mis-regulation in cancer | WHSC1, NUPR1 | −1.68 | |
hsa04010 | MAPK signaling pathway | CACNG8, MAP3K5, DUSP6, RPS6KA2, RPS6KA5, PDGFRA | −1.76 | |
hsa05219 | Bladder cancer | MMP1, VEGFA, E2F1 | −1.80 | |
hsa03320 | PPAR signaling pathway | MMP1, SLC27A2, PCK2 | −1.80 | |
hsa01212 | Fatty acid metabolism | HADH, E2F2 | −1.93 | |
hsa05205 | Proteoglycans in cancer | VEGFA, VTN | −1.97 | |
hsa04064 | NF-kappa B signaling pathway | TRAF5 | −2.15 | |
hsa05215 | Prostate cancer | E2F1 | −2.24 | |
hsa04152 | AMPK signaling pathway | CCNA2, CFTR, PCK2 | −2.26 | |
Hsa05223 | Non-small cell lung cancer | E2F2 | −4.03 |
